Portal de investigación
Foxp3 Silencing with Antisense Oligonucleotide Improves Immunogenicity of an Adjuvanted Recombinant Vaccine against Sporothrix schenckii
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Batista-Duharte, A
- Portuondo, DL
- Tellez-Martinez, D
- Olivera, G
- Fernandez-Delgado, M
- Javega, B
- Herrera, G
- Martinez, A
- Costa, PI
- Carlos, IZ
Grupos
Abstract
Background: In recent years, there has been great interest in developing molecular adjuvants based on antisense oligonucleotides (ASOs) targeting immunosuppressor pathways with inhibitory effects on regulatory T cells (Tregs) to improve immunogenicity and vaccine efficacy. We aim to evaluate the immunostimulating effect of 2 ' OMe phosphorothioated Foxp3-targeted ASO in an antifungal adjuvanted recombinant vaccine. Methods: The uptake kinetics of Foxp3 ASO, its cytotoxicity and its ability to deplete Tregs were evaluated in murine splenocytes in vitro. Groups of mice were vaccinated with recombinant enolase (Eno) of Sporothix schenckii in Montanide Gel 01 adjuvant alone or in combination with either 1 mu g or 8 mu g of Foxp3 ASO. The titers of antigen-specific antibody in serum samples from vaccinated mice (male C57BL/6) were determined by ELISA (enzyme-linked immunosorbent assay). Cultured splenocytes from each group were activated in vitro with Eno and the levels of IFN-gamma and IL-12 were also measured by ELISA. The results showed that the anti-Eno antibody titer was significantly higher upon addition of 8 mu M Foxp3 ASO in the vaccine formulation compared to the standard vaccine without ASO. In vitro and in vivo experiments suggest that Foxp3 ASO enhances specific immune responses by means of Treg depletion during vaccination. Conclusion: Foxp3 ASO significantly enhances immune responses against co-delivered adjuvanted recombinant Eno vaccine and it has the potential to improve vaccine immunogenicity.
Datos de la publicación
- ISSN/ISSNe:
- 1661-6596, 1661-6596
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/ijms22073470
- PubMed:
- 33801683
- Factor de Impacto:
- 1,176 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES MDPI AG
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- antisensense oligonucleotide; Foxp3; regulatory T cells; vaccine immunogenicity; Sporothrix schenckii
Proyectos y Estudios Clínicos
CONTRATOS DE TECNICOS DE APOYO A LA INVESTIGACION EN EL SISTEMA NACIONAL DE SALUD
CA12/00052 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
PLATAFORMA DE UNIDADES DE INVESTIGACION CLINICA Y ENSAYOS CLINICOS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
PT13/0002/0032 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
PIE13/00046 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
IMPLANTACIÓN DE LA MEDICINA PERSONALIZADA EN ONCOLOGÍA PEDIÁTRICA: FARMACOGENÉTICA, EPIGENÉTICA, METABOLÓMICA Y LOS SISTEMAS DE INFORMACIÓN.
Investigador Principal: MARÍA JOSÉ HERRERO CERVERA
MJH-CIS-2016-01 . FUNDACION MUTUA MADRILEÑA . 2016
MODELOS DE HÍGADO AISLADO PERFUNDIDO PARA EL RESCATE DE ÓRGANOS Y TRASLACIÓN DE LA TERAPIA GÉNICA EN EL TRASPLANTE: ESCENARIOS HUMANO "EX VIVO" Y PORCINO "IN VIVO"
Investigador Principal: RAFAEL LÓPEZ ANDÚJAR
2017_0270_CRC_LOPEZ . FUNDACION MUTUA MADRILEÑA . 2017
Desarrollo de nanoterapias anti-inflamatorias en retinosis pigmentaria.
Investigador Principal: REGINA RODRIGO NICOLÁS
PI18/00252 . INSTITUTO DE SALUD CARLOS III . 2019
Terápia génica no-viral con 1L 10 para el tratamiento de la enfermedad inflamatoria intestinal. Estudio preliminar con piezas de cólon humano ex vivo.
Investigador Principal: MATTEO FRASSON
PI18/01658 . INSTITUTO DE SALUD CARLOS III . 2019
Randomized, double-blind, placebo-controlled study to evaluate the effect of metformin, an activator of AMPK, on cognitive decline in patients with Huntington's disease. TEMET-HD
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
ICI19/00014 . INSTITUTO DE SALUD CARLOS III . 2020
DETERMINANTES GENÉTICOS Y BIOMARCADORES GENÓMICOS DE RIESGO EN PACIENTES CON INFECCIÓN POR CORONAVIRUS SARS-COV-2.
Investigador Principal: MARÍA JOSÉ HERRERO CERVERA
COV20/00622 . INSTITUTO DE SALUD CARLOS III; CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (CIBER) . 2020
Plataforma ISCIII de soporte para la investigación clínica independiente.
Investigador Principal: PILAR NOS MATEU
PT20/00092 . INSTITUTO DE SALUD CARLOS III . 2021
ESTUDIO FARMACOGENÉTICO DEL TRATAMIENTO EN LA INSUFICIENCIA CARDIACA TERMINAL: INHIBIDORES DE LA ECA, B-BLOQUEANTES Y ANTIALDOSTERÓNICOS.
Investigador Principal: MARÍA JOSÉ HERRERO CERVERA
HLF-ECA-2015-01
Cita
Batista A,SENDRA L,HERRERO MJ,Portuondo DL,Tellez D,Olivera G,Fernandez M,Javega B,Herrera G,Martinez A,Costa PI,Carlos IZ,ALINO SF. Foxp3 Silencing with Antisense Oligonucleotide Improves Immunogenicity of an Adjuvanted Recombinant Vaccine against Sporothrix schenckii. Int. J. Mol. Sci. 2021. 22. (7):3470. IF:6,208. (1).